Research Article
BibTex RIS Cite

İnsan Serum Paraoksonaz-1 (PON1) Enzim Aktivitesi Üzerine Zoledronik Asit’in İn Vitro İnhibisyon Etkisinin Araştırılması

Year 2020, Volume: 9 Issue: 2, 185 - 189, 30.12.2020

Hakan Söyüt Yakup Ulutaş Ekrem Köksal

https://doi.org/10.46810/tdfd.755604
Cited By: 1

Abstract

Zoledronik asit azot içeren bir bisfosfonattır. Güçlü bir kemik rezorpsiyon inhibitörüdür. Osteoklast aktiviteyi inhibe eder. PON1 organofosfatların, aril esterlerin ve laktonların hidrolizini katalize eder. PON1, ateroskleroz dahil olmak üzere birçok vasküler hastalıkla ilişkili olduğu bilinen Düşük Yoğunluklu Lipoprotein (LDH) ve Yüksek Yoğunluklu Lipoprotein'i (HDL), oksidatif strese karşı koruyarak bir antioksidan enzim olarak görev yapar. Aslında, daha yüksek PON1 aktivitesi aterosklerozun önlenmesinde önemli bir rol oynar. Epidemiyolojik çalışmalar düşük PON1 aktivitesinin artmış kardiyovasküler olay riski ve kardiyovasküler hastalık riski ile ilişkili olduğunu göstermektedir. Bu makalede, in vitro koşullarda insan serumunda PON1 enzim aktivitesi üzerine zoledronik asit kemoterapik ilacının inhibisyon etkisini araştırdık.

Keywords

Paraoksonaz İnhibisyon Zoledronik asit

References

  • [1] Li EC, Davis, LE. Zoledronic acid: A new parenteral bisphosphonate. Clin Ther. 2003;25(11):2669-708.
  • [2] Aviram M, Rosenblat M, Bisgair CL. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest. 1998;101(8):2215-57.
  • [3] Mackness MI, Boullier A, Hennuyer N. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. Biochem Biophys Res Commun. 2000;269(1):232–36.
  • [4] Liang H. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med. 2003;81(12):766–79.
  • [5] Deakin SP, Bioletto S, Bochaton-Piallat M, James RW. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radic Biol Med. 2011;50(1):102–9.
  • [6] Teiber JF, Draganov DI, La Du BN. Lactonase and lactonizing of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem Pharmacol. 2003;66(6):887-96.
  • [7] Rozenberg O, Shih SD, Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis. 2005;181(1):9-18.
  • [8] Jaouad L, Milochevitch C, Khalil A. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic Res. 2003;37(1):77–83.
  • [9] Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The Paraoxonase gene family and atherosclerosis. Free Radic Biol Med. 2005;38(2):153– 63.
  • [10] Aviram M, Rosenblat, M. Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods Mol Biol. 2008;477:259–76.
  • [11] Sinan S, Kockar F, Gencer N, Yildirim H, Arslan O. Effects of some antibiotics on paraoxonase from human serum in vitro and from mouse serum and liver in vivo. Biological and Pharmaceutical Bulletin. 2006;29(8):1559–63.
  • [12] Alici HA, Ekinci D, Beydemir Ş. Intravenous anesthetics inhibit human paraoxonase-I (PON1) activity in vitro and in vivo. Clin Biochem. 2008;41(16-17):1384-90.
  • [13] Ekinci D, Beydemir S. Effect of some analgesic on purified paraoxonase-1 from human serum. J Enzyme Inhib Med Chem. 2009;24(4):1034-39.
  • [14] Türkeş C, Söyüt H, Beydemir Ş. In vitro inhibitory effects of palonosetron hydrochloride, bevacizumab and cyclophosphamide on purified paraoxonase-I (hPON1) from human serum. Environ Toxicol Pharmacol. 2016;42:252–57.
  • [15] Türkeş C. Investigation of potential paraoxonase-I inhibitors by kinetic and molecular docking studies: chemotherapeutic drugs. Protein Pept Lett. 2019;26(6):392-402.
  • [16] Türkeş C, Beydemir Ş, Küfrevioğlu, OI. In Vitro and In Silico Studies on the Toxic Effects of Antibacterial Drugs as Human Serum Paraoxonase 1 Inhibitor. Chemistry Select. 2016;4(33):9731 –36.

Year 2020, Volume: 9 Issue: 2, 185 - 189, 30.12.2020

Hakan Söyüt Yakup Ulutaş Ekrem Köksal

https://doi.org/10.46810/tdfd.755604
Cited By: 1

Abstract

References

  • [1] Li EC, Davis, LE. Zoledronic acid: A new parenteral bisphosphonate. Clin Ther. 2003;25(11):2669-708.
  • [2] Aviram M, Rosenblat M, Bisgair CL. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest. 1998;101(8):2215-57.
  • [3] Mackness MI, Boullier A, Hennuyer N. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. Biochem Biophys Res Commun. 2000;269(1):232–36.
  • [4] Liang H. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med. 2003;81(12):766–79.
  • [5] Deakin SP, Bioletto S, Bochaton-Piallat M, James RW. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radic Biol Med. 2011;50(1):102–9.
  • [6] Teiber JF, Draganov DI, La Du BN. Lactonase and lactonizing of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem Pharmacol. 2003;66(6):887-96.
  • [7] Rozenberg O, Shih SD, Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis. 2005;181(1):9-18.
  • [8] Jaouad L, Milochevitch C, Khalil A. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic Res. 2003;37(1):77–83.
  • [9] Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The Paraoxonase gene family and atherosclerosis. Free Radic Biol Med. 2005;38(2):153– 63.
  • [10] Aviram M, Rosenblat, M. Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods Mol Biol. 2008;477:259–76.
  • [11] Sinan S, Kockar F, Gencer N, Yildirim H, Arslan O. Effects of some antibiotics on paraoxonase from human serum in vitro and from mouse serum and liver in vivo. Biological and Pharmaceutical Bulletin. 2006;29(8):1559–63.
  • [12] Alici HA, Ekinci D, Beydemir Ş. Intravenous anesthetics inhibit human paraoxonase-I (PON1) activity in vitro and in vivo. Clin Biochem. 2008;41(16-17):1384-90.
  • [13] Ekinci D, Beydemir S. Effect of some analgesic on purified paraoxonase-1 from human serum. J Enzyme Inhib Med Chem. 2009;24(4):1034-39.
  • [14] Türkeş C, Söyüt H, Beydemir Ş. In vitro inhibitory effects of palonosetron hydrochloride, bevacizumab and cyclophosphamide on purified paraoxonase-I (hPON1) from human serum. Environ Toxicol Pharmacol. 2016;42:252–57.
  • [15] Türkeş C. Investigation of potential paraoxonase-I inhibitors by kinetic and molecular docking studies: chemotherapeutic drugs. Protein Pept Lett. 2019;26(6):392-402.
  • [16] Türkeş C, Beydemir Ş, Küfrevioğlu, OI. In Vitro and In Silico Studies on the Toxic Effects of Antibacterial Drugs as Human Serum Paraoxonase 1 Inhibitor. Chemistry Select. 2016;4(33):9731 –36.
There are 16 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Hakan Söyüt 0000-0002-0361-7458

Yakup Ulutaş 0000-0002-9839-9536

Ekrem Köksal 0000-0002-1026-972X

Publication Date December 30, 2020
Published in Issue Year 2020 Volume: 9 Issue: 2

Cite

APA Söyüt, H., Ulutaş, Y., & Köksal, E. (2020). İnsan Serum Paraoksonaz-1 (PON1) Enzim Aktivitesi Üzerine Zoledronik Asit’in İn Vitro İnhibisyon Etkisinin Araştırılması. Türk Doğa Ve Fen Dergisi, 9(2), 185-189. https://doi.org/10.46810/tdfd.755604
AMA Söyüt H, Ulutaş Y, Köksal E. İnsan Serum Paraoksonaz-1 (PON1) Enzim Aktivitesi Üzerine Zoledronik Asit’in İn Vitro İnhibisyon Etkisinin Araştırılması. TJNS. December 2020;9(2):185-189. doi:10.46810/tdfd.755604
Chicago Söyüt, Hakan, Yakup Ulutaş, and Ekrem Köksal. “İnsan Serum Paraoksonaz-1 (PON1) Enzim Aktivitesi Üzerine Zoledronik Asit’in İn Vitro İnhibisyon Etkisinin Araştırılması”. Türk Doğa Ve Fen Dergisi 9, no. 2 (December 2020): 185-89. https://doi.org/10.46810/tdfd.755604.
EndNote Söyüt H, Ulutaş Y, Köksal E (December 1, 2020) İnsan Serum Paraoksonaz-1 (PON1) Enzim Aktivitesi Üzerine Zoledronik Asit’in İn Vitro İnhibisyon Etkisinin Araştırılması. Türk Doğa ve Fen Dergisi 9 2 185–189.
IEEE H. Söyüt, Y. Ulutaş, and E. Köksal, “İnsan Serum Paraoksonaz-1 (PON1) Enzim Aktivitesi Üzerine Zoledronik Asit’in İn Vitro İnhibisyon Etkisinin Araştırılması”, TJNS, vol. 9, no. 2, pp. 185–189, 2020, doi: 10.46810/tdfd.755604.
ISNAD Söyüt, Hakan et al. “İnsan Serum Paraoksonaz-1 (PON1) Enzim Aktivitesi Üzerine Zoledronik Asit’in İn Vitro İnhibisyon Etkisinin Araştırılması”. Türk Doğa ve Fen Dergisi 9/2 (December 2020), 185-189. https://doi.org/10.46810/tdfd.755604.
JAMA Söyüt H, Ulutaş Y, Köksal E. İnsan Serum Paraoksonaz-1 (PON1) Enzim Aktivitesi Üzerine Zoledronik Asit’in İn Vitro İnhibisyon Etkisinin Araştırılması. TJNS. 2020;9:185–189.
MLA Söyüt, Hakan et al. “İnsan Serum Paraoksonaz-1 (PON1) Enzim Aktivitesi Üzerine Zoledronik Asit’in İn Vitro İnhibisyon Etkisinin Araştırılması”. Türk Doğa Ve Fen Dergisi, vol. 9, no. 2, 2020, pp. 185-9, doi:10.46810/tdfd.755604.
Vancouver Söyüt H, Ulutaş Y, Köksal E. İnsan Serum Paraoksonaz-1 (PON1) Enzim Aktivitesi Üzerine Zoledronik Asit’in İn Vitro İnhibisyon Etkisinin Araştırılması. TJNS. 2020;9(2):185-9.

Cited By

Inhibition Effects of Oncological Drugs for Treatment of Cancer, on Paraoxonase-1 Enzyme (PON1) Activity and Cardiovascular Toxicity
International Journal of Pharmacology
https://doi.org/10.3923/ijp.2023.34.39
 Download Cover Image

This work is licensed under the Creative Commons Attribution-Non-Commercial-Non-Derivable 4.0 International License.